Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
Lantern Pharma Inc. filed a Form 8-K dated September 23, 2026, under Item 7.01, Regulation FD Disclosure. The company announced a live webinar concerning Open-Medicine AI, described as a multi-agentic artificial intelligence platform for drug development.
Financial and Operating Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, liquidity, or other quantitative financial metrics.
Material Changes Versus the Prior Comparable Period
The filing does not report financial or operating changes versus a prior comparable period. It only announces topics for a company-hosted webinar.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide financial guidance, quantitative outlook, risk updates, contingencies, or unusual accounting items. Exhibit 99.1 is a press release describing the webinar topics, but the press release text is not included in the provided filing content.
The Item 7.01 disclosure and Exhibit 99.1 are furnished, not filed, for purposes of Section 18 of the Exchange Act and are not incorporated by reference into other filings unless specifically incorporated.
Important Facts to Verify
- Review Exhibit 99.1 for the specific Open-Medicine AI announcements and claims discussed during the webinar.
- Verify whether the webinar included development milestones, partnerships, commercialization plans, or financial implications not stated in the Form 8-K body.
- Assess any forward-looking statements, technology risks, clinical-development risks, and funding requirements associated with the platform.
- Confirm that no financial metrics or guidance were provided in the accompanying press release or webinar materials.